Clinical trial NCT06809205: Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study
Official title: Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: BPH with Other Lower Urinary Tract Symptoms
Keywords: Tamsulosin, tadalafil, BPH and LUTS
Lead sponsor: Fayoum University Hospital
Sponsor class: OTHER
First posted: 2025-02-05
Enrollment: 95
Sex: MALE
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Abstract:

Objective: To examine the influence of tadalafil and tamsulosin versus their combinations in the treatment of lower urinary tract symptoms in mildly enlarged prostates below 40 ml in volume.

Materials and methods: A prospective randomized study was done at Fayoum and Beni-Suef University Hospitals in Egypt from December 2022 to August 2023. A total of 95 male participants aged over 45 years, all presenting with mild to intense lower urinary tract symptoms, were enrolled. Participants were randomized into three groups: Group A was administered Tamsulosin (0.4 mg per day), Group B was administered tadalafil (5 mg per day), and Group C was administered a mixture of both medications. The study assessed multiple parameters, the primary endpoint parameter was the International Prostate Symptom Score (IPSS) and the other secondary parameters were the five-item International Index of Erectile Function (IIEF-5), maximum urinary flow rate (Q-max), post-void residual urine (PVR), and the quality of life (QoL). At baseline, these parameters were assessed, followed by evaluations at 1, 3, and 6 months after treatment.

Key words. Tamsulosin, tadalafil, BPH and LUTS.

Detailed description: Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 ml: A Prospective Comparative Study.

Mohamed Mahmoud Dogha\*1, Mahmoud Shoukry ElAdawy¹, Rabie M Ibrahim², Ahmed Yousef2, ,Samia Heikal3, Mahmoud AbdElhamid4, Ahmed Abdalgalil1, Hossam Shaker¹.

1. Department of Urology, Faculty of Medicine, Fayoum University, Egypt
2. Department of Urology, Faculty of Medicine, Beni-suef University, Egypt
3. Diagnostic Radiology Department, National Cancer Institute, Cairo University
4. Department of Urology, Faculty of Medicine, Cairo University, Egypt

   \*Email: mma16@fayoum.edu.eg

   Introduction:

   Lower urinary tract symptoms (LUTS) are frequently triggered by benign prostatic enlargement (BPE), such as storage symptoms like nocturia, frequency, and urgency, along with voiding symptoms like hesitancy, weak flow, and straining, all of which can substantially impact the total quality of life for a patient. \[1, 2\] Treatment options for LUTS related to BPE include surgical intervention, pharmacotherapy (such as 5-alpha reductase inhibitors, phosphodiesterase 5 inhibitors, alpha blockers, and phytotherapies) and other approaches. \[3, 4\] alpha blockers work by reducing prostate tone through the inhibition of noradrenaline's influence on smooth muscle cells in the prostate. \[5\] Although the complete clinical effects of alpha blockers may take a few weeks to become evident, notable improvements can often be seen within hours to days. \[6\] These medications are effective in alleviating both storage and voiding LUTS without reducing prostate size, although they tend to be more effective in patients with a prostate size of lower than 40 ml. \[7-10\] Despite these advancements in the Qmax and the IPSS can be sustained for at least four years with alpha blocker therapy. phosphodiesterase 5 inhibitors reduce smooth muscle tone in the urethra, prostate, and detrusor, and their chronic use may raise oxygenation, and blood flow, and potentially diminish chronic inflammation in the lower urinary tract. However, the precise way in which they influence LUTS is still not well understood. \[11-13\] Our study aimed to examine the efficacy of tamsulosin versus tadalafil, and their combination; in treating LUTS/BPE in individuals with a prostate size ≤ 40 ml.

   Materials and methods:

   Our prospective randomized clinical assessment was performed from December 2022 to August 2023 at the Urology Department of Fayoum and Beni-suef University Hospitals Randomization was carried out using a sealed envelope method. The Review Board, an ethical commission, received approval (approval number: R 450) from the hospital ethics committee at the Fayoum University Faculty of Medicine. After receiving a detailed explanation of the study's objectives, participants were made aware of the purpose and benefits of the analysis. The participants in the study provided their consent willingly. Moreover, written consent was secured in advance. The confidentiality of the information collected was assured to the participants. Inclusion criteria were male patients aged ≥ 45years with prostate volume less than 40 ml, with mild to intense LUTS/BPH as regard to IPSS.The exclusion criteria included a prostate-specific antigen (PSA) level exceeding 4 ng/mL, a prostate volume exceeding 40 ml, an amount of remaining urine of 300 mL or more, the utilize of 5-alpha reductase inhibitors (5-ARIs) in the past three months, a history of prostate surgery or malignancy, urethral stricture, urinary retention, bladder stones, neurological diseases affecting bladder function, cardiovascular diseases, and treatment with nitrates. Patients were divided into three groups: group A was administered 0.4 mg tamsulosin per day, group B was administered tadalafil 5mg daily, and group C was administered a mixture of both tadalafil and tamsulosin. Each patient underwent assessments at four distinct intervals: at presentation and after 1, 3, and 6 months of treatment. At the initial presentation, comprehensive assessments were performed, while follow-up visits included evaluations of the IIEF-5, IPSS, uroflowmetry, PVR and IPSS QoL scores. The results from the three groups were recorded at all four visits and subsequently compared and analyzed statistically.All ultrasounds were performed by the same radiologist to eliminate the bias of different radiology operators Statistical methods: G \* power was used to determine a minimum sample size of 90. The target sample size was computed with an alpha value of 0.05, an effect size of 0.25, and a power of study of 0.8. The data were analyzed using SPSS (Statistical Package for the Social Sciences) version 28 (IBM Corp., Armonk, NY, USA). The mean and standard deviation of the data served as a summary. Groups were compared using analysis of variance (ANOVA), followed by a post-hoc multiple comparisons test (Chan, 2003). Data was double checked for normality using normality plots and Shapiro Wilk test and proved not to be deviated from normal distribution. According to \[14\], statistical significance was defined as a p-value less than 0.05.

   Declarations Ethics approval and consent to participate: The Review Board, an ethical commission, received approval (approval number: R 450) from the hospital ethics committee at the Fayoum University Faculty of Medicine in accordance with the declaration of Helsinki. And every participant provided a cleared and detailed consent.

   Conflict of Interest: None. Funding: None.

   Authors' contributions:

   Mohamed Mahmoud Dogha conducted conception and design of the study. Mahmoud S. ElAdawy and Mahmoud AbdElhamid performed interpretation of data, work design. Hossam shaker, Samia Heikal and Ahmed Abdalgalil did conception and design of the study, drafted the manuscript, interpretation of data. Rabie M. Ibrahim and Ahmed Yousif drafted the manuscript, Data analysis

   Abbreviations:
5. ARIs: 5-alpha reductase inhibitors BPE: Benign prostatic enlargement IEFF-5: International Index of Erectile Function 5 items IPSS: international prostate symptom score LUTS: Lower urinary tract symptoms PDE5Is: phosphodiesterase type 5 inhibitors PSA: Prostate-specific antigen Qmax: maximum urinary flow rate QoL: quality of life

Eligibility criteria: Inclusion Criteria:

* Inclusion criteria were male patients aged ≥ 45years with prostate volume less than 40 ml, with mild to intense LUTS/BPH as regard to IPSS.

Exclusion Criteria:

* The exclusion criteria included a prostate-specific antigen (PSA) level exceeding 4 ng/mL, a prostate volume exceeding 40 ml, an amount of remaining urine of 300 mL or more, the utilize of 5-alpha reductase inhibitors (5-ARIs) in the past three months, a history of prostate surgery or malignancy, urethral stricture, urinary retention, bladder stones, neurological diseases affecting bladder function, cardiovascular diseases, and treatment with nitrates.

Primary outcomes:
measure: IPSS (International Prostate Symptom Score)
timeFrame: at presentation, 1,3 and 6 month after treatment
Secondary outcomes:
measure: IIEF-5 (five-item International Index of Erectile Function)
timeFrame: at presentation, 1,3 and 6 month after treatment
measure: Q-max (maximum urinary flow rate)
timeFrame: at presentation, 1,3 and 6 month after treatment
measure: PVR (post-void residual urine)
timeFrame: at presentation, 1,3 and 6 month after treatment
measure: QoL (quality of life)
timeFrame: at presentation, 1,3 and 6 month after treatment
Other outcomes:
Locations:
city: Fayoum
country: Egypt
facility: Mohamed Mahmoud Dogha
state: Fayoum Governorate
Study officials:
References:
citation: Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO, Gravas S. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015 Jun;67(6):1099-1109. doi: 10.1016/j.eururo.2014.12.038. Epub 2015 Jan 19.
citation: MacDonald R, Brasure M, Dahm P, Olson CM, Nelson VA, Fink HA, Risk MC, Rwabasonga B, Wilt TJ. Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review. Aging Male. 2019 Mar;22(1):1-11. doi: 10.1080/13685538.2018.1434503. Epub 2018 Feb 2.
citation: Morton A, Williams M, Perera M, Teloken PE, Donato P, Ranasinghe S, Chung E, Bolton D, Yaxley J, Roberts MJ. Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. BJU Int. 2020 Sep;126 Suppl 1:18-26. doi: 10.1111/bju.15098. Epub 2020 Jun 17.
citation: Yamanishi T, Kaga K, Sakata K, Yokoyama T, Kageyama S, Fuse M, Tokunaga S. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourol Urodyn. 2020 Feb;39(2):804-812. doi: 10.1002/nau.24285. Epub 2020 Jan 21.
citation: Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006 Feb;147 Suppl 2(Suppl 2):S88-119. doi: 10.1038/sj.bjp.0706619.